Go Deep
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,845 | -4.3 | 1.76 | 0.03 | 2,877.01 |
| Oct 2026 | 19,741 | -4.4 | 1.80 | 0.03 | 2,940.52 |
| Oct 2026 | 19,554 | -4.6 | 1.88 | 0.03 | 3,069.14 |
| Oct 2026 | 19,692 | -4.5 | 1.82 | 0.03 | 2,966.47 |
| Oct 2026 | 19,199 | -5.0 | 2.03 | 0.03 | 3,309.09 |
| Oct 2026 | 18,958 | -5.2 | 2.13 | 0.03 | 3,474.07 |
| Oct 2026 | 18,884 | -5.3 | 2.16 | 0.03 | 3,516.57 |
| Oct 2026 | 18,883 | -5.3 | 2.16 | 0.03 | 3,510.39 |
Agios Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 44,745,000.0 | 20,746,000.0 | 19,967,000.0 | 12,880,000.0 |
| Net Profit | -100,703,000.0 | -99,111,000.0 | -108,039,000.0 | -103,433,000.0 |
| EPS | -1.7 | -1.7 | — | -1.8 |
Agios Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 54,028,000.0 | 36,498,000.0 | 26,823,000.0 | 14,240,000.0 | — |
| Net Profit | -412,781,000.0 | 673,725,000.0 | -352,088,000.0 | -231,801,000.0 | — |
| EPS | -7.1 | 11.9 | -6.3 | -4.2 | — |
Agios Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,297,225,000.0 | 1,663,199,000.0 | 937,118,000.0 | 1,238,718,000.0 | — |
| Total Liabilities | 104,111,000.0 | 122,243,000.0 | 126,099,000.0 | 137,904,000.0 | — |
| Total Equity | 1,193,114,000.0 | 1,540,956,000.0 | 811,019,000.0 | 1,100,814,000.0 | — |
Owes vs Owns
Agios Pharmaceuticals, Inc. owed $0.07 for every $1 it owned in Jun 2026, down from $0.11 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.07× | 0.08× | 0.07× | 0.13× | 0.11× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Agios Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 65.9%Receivables 0.8%Inventory 2.5%Fixed assets (tangible) 3.2%Long-term investments 23.9%Other assets 3.7%
How it's funded — Dec 2025
Short-term debt 1.4%Long-term debt 1.7%Payables 1.4%Other liabilities 3.5%Shareholders' equity 92.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 854.4 | 893.7 | 776.9 | 783.1 |
| Receivables | 10.6 | 4.1 | 2.8 | 2.2 |
| Inventory | 32.9 | 27.6 | 19.1 | 8.5 |
| Fixed assets (tangible) | 41.2 | 54.6 | 69.8 | 88.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 310.0 | 638.3 | 29.4 | 313.9 |
| Other assets | 48.1 | 44.9 | 39.1 | 42.9 |
| Liabilities & equity | ||||
| Short-term debt | 18.4 | 16.8 | 15.0 | 13.7 |
| Long-term debt | 21.8 | 40.2 | 57.0 | 72.0 |
| Payables | 18.4 | 16.6 | 9.8 | 18.6 |
| Other liabilities | 45.5 | 48.6 | 44.3 | 33.6 |
| Shareholders' equity | 1,193.1 | 1,541.0 | 811.0 | 1,100.8 |
| Net tangible assets | 1,193.1 | 1,541.0 | 811.0 | 1,100.8 |
Agios Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -372,977,000.0 | -389,841,000.0 | -296,062,000.0 | -309,478,000.0 | — |
| Investing Activities | 377,184,000.0 | 363,441,000.0 | 239,575,000.0 | 243,261,000.0 | — |
| Financing Activities | 8,676,000.0 | 14,442,000.0 | 5,433,000.0 | 2,350,000.0 | — |